Neurol Case Rep | Volume 4, Issue 1 | Case Study | Open Access
Lisa BE Shields1, Vasudeva G Iyer2, Yi Ping Zhang1 and Christopher B Shields1,3*
1Department of Neurology, Norton Neuroscience Institute, USA 2Department of Neurology, Neurodiagnostic Center of Louisville, USA 3Department of Neurological Surgery, University of Louisville School of Medicine, Louisville, USA
*Correspondance to: Christopher B Shields
Fulltext PDFBackground: Paraneoplastic Neurologic Syndrome (PNS) refers to the presence of cancer with non-metastatic or therapeutic manifestations of neurological disease. PNS has been attributed to tumor secretion of hormones, peptides, or cytokines or an immune response against the tumor. Case Description: Here, we report a patient with gradual weakness of the lower extremities bilaterally. He underwent a transurethral resection of the prostate 2 years earlier. The pathology revealed a Gleason 9 poorly differentiated adenocarcinoma. Following 6 cycles of docetaxel and 3 months of abiraterone and prednisone, the patient started enzalutamide. On exam, weakness of the dorsiflexors of the ankles, quadriceps, and hip flexors were noted bilaterally. There was decreased pinprick sensation over the feet. The EMG/NCV confirmed a sensorimotor peripheral polyneuropathy of the upper and lower extremities. The patient declined any further medical testing or treatment and died 8 weeks later. Conclusion: Neurosurgeons and neurologists should be aware of PNS in patients with prostate cancer who experience a sensorimotor peripheral polyneuropathy of the upper and lower extremities. EMG/NCV and antibody detection are valuable tools in confirming and treating this rare condition.
Peripheral neuropathy; Paraneoplastic; Prostate cancer; Electromyography; Nerve conduction study
Shields LBE, Iyer VG, Zhang YP, Shields CB. Paraneoplastic Sensorimotor Peripheral Neuropathy in Prostate Cancer. Neurol Case Rep. 2021;4(1):1022..